Company Valuation: Transgene

Data adjusted to current consolidation scope
Fiscal Period: December 2021 2022 2023 2024 2025 2026 2027 2028
Market Cap 1 247.8 164.8 137.8 89.75 262.9 194.7 - -
Change - -33.52% -16.38% -34.86% 192.89% -25.92% - -
Enterprise Value (EV) 1 214.9 151.4 139.4 83.48 153.1 125.5 187 213.3
Change - -29.53% -7.95% -40.12% 83.37% -17.99% 48.99% 14.06%
P/E -12.1x -5.02x -6.23x -2.34x -3.69x -5.08x -3.23x -7.9x
PBR 3.69x 4.38x 8.82x 5.92x 1.14x 2.37x 8.89x -71.1x
PEG - -0.1x 0.2x -0.1x 0.4x 0.1x -0.1x 0.1x
Capitalization / Revenue 14.2x 15.9x 17.4x 14.1x 36.5x 27x 27x 3.42x
EV / Revenue 12.3x 14.6x 17.6x 13.1x 21.2x 17.4x 26x 3.74x
EV / EBITDA -10.2x -5.37x -4.9x -2.43x -4.54x -2.88x -2.67x -9.04x
EV / EBIT -9.14x -5.06x -4.64x -2.34x -4.37x -2.83x -2.64x -7.28x
EV / FCF -6.59x -6.94x -1,408x -3.12x -1.07x -3.16x -3.1x -8.5x
FCF Yield -15.2% -14.4% -0.07% -32% -93.4% -31.6% -32.3% -11.8%
Dividend per Share 2 - - - - - - - -
Rate of return - - - - - - - -
EPS 2 -0.21 -0.33 -0.22 -0.29 -0.26 -0.14 -0.22 -0.09
Distribution rate - - - - - - - -
Net sales 1 17.41 10.34 7.9 6.353 7.21 7.2 7.2 57
EBITDA 1 -21 -28.22 -28.48 -34.38 -33.73 -43.6 -70.1 -23.6
EBIT 1 -23.52 -29.9 -30.05 -35.66 -35.06 -44.3 -70.8 -29.3
Net income 1 -19.54 -32.8 -22.33 -33.97 -37.52 -38.2 -61.6 -25.3
Net Debt 1 -32.93 -13.31 1.629 -6.274 -109.8 -69.2 -7.7 18.6
Reference price 2 2.5400 1.6580 1.3700 0.6800 0.9600 0.7110 0.7110 0.7110
Nbr of stocks (in thousands) 97,576 99,370 100,566 131,990 273,827 273,882 - -
Announcement Date 16/03/22 16/03/23 27/03/24 27/03/25 24/03/26 - - -
1EUR in Million2EUR
Estimates

P/E, Detailed evolution



P/E (Y) EV / Sales (Y) EV / EBITDA (Y) Dividend Yield (Y) Capi.($)
-5.11x17.59x-2.9x - 216M
17.13x6.55x12.55x1.74% 65.56B
32.67x8.73x28.87x0.07% 60.41B
38.83x6.91x20.67x0.84% 55.76B
44.13x6.17x29.36x-.--% 46.98B
34.55x3.29x14.19x-.--% 43.63B
36.23x8.96x23.37x0.36% 36.7B
-19.98x53.61x-21.71x-.--% 36.09B
41.91x8.08x27.1x-.--% 32.9B
-74.98x14.21x-76.38x-.--% 26.96B
Average 14.54x 13.41x 5.51x 0.33% 41B
Weighted average by Cap. 21.74x 11.58x 11.41x 0.44%

Y-o-Y evolution of P/E

Valuation ratios - P/E - Transgene

Historical PBR trend

Valuation ratios - PBR - Transgene

Evolution Enterprise Value / Sales

Valuation ratios - VE_REV - Transgene

Change in Enterprise Value/EBITDA

Valuation ratios - VE_EBITDA - Transgene